1. OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis. (22nd February 2019) Authors: Schreiber, Stefan; Peyrin-Biroulet, Laurent; Loftus, Edward V; Danese, Silvio; Colombel, Jean-Frederic; Abhyankar, Brihad; Chen, Jingjing; Rogers, Raquel; Lirio, Richard A; Bornstein, Jeffrey D; Sands, Bruce E Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S612 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study. (17th March 2022) Authors: Hyams, Jeffrey S; Turner, Dan; Cohen, Stanley A; Szakos, Erzsébet; Kowalska-Duplaga, Kinga; Ruemmele, Frank; Croft, Nicholas M; Korczowski, Bartosz; Lawrence, Promise; Bhatia, Siddharth; Kadali, Harisha; Chen, Chunlin; Sun, Wan; Rosario, Maria; Kabilan, Senthil; Treem, William; Rossiter, Guillerm... Journal: Journal of Crohn's and colitis Issue: Volume 16:Number 8(2022) Page Start: 1243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗